Arthritis & Rheumatism, Volume 60,
October 2009 Abstract Supplement

The 2009 ACR/ARHP Annual Scientific Meeting
Philadelphia October 16-21, 2009.


Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Profile in Patients with Morphea

Kellet,  Cristián Vera, Dutz,  Jan P.

Purpose:

Systemic autoimmune disease is more common in patients with morphea. Rheumatoid factor (RF) has been reported in a subset of patients with morphea, but the significance of this remains unclear. Anti-cyclic citrullinated peptide antibody (anti-CCP) is a sensitive and specific marker for the diagnosis of rheumatoid arthritis that has not been examined in morphea.The aim of this study was to determine the presence of RF and anti-CCP antibodies in patients with morphea, who attended a Dermatology Connective Tissue Disease Clinic and to assess any association between the presence of RF and anti-CCP, disease activity and clinical manifestations.

Method:

This was a retrospective study. We reviewed all the charts of patients with a diagnosis of morphea assessed between January 2006 and December 2008.

Results:

54/72 patients with morphea had at least one RF assessment (43 women and 11 men, mean age 44.3 years). RF was negative (< 10 kU/L) in 48 % (26/54) of patients, and it was positive either at low (>10 kU/L and <30 kU/L) or high (>30 kU/L) titers in 52% (28/54). There was a trend to generalised versus linear morphea in patients with a high positive RF compared to those with a negative RF (9/12 versus 14/26). There was a trend to active disease in those patients with a high positive RF compared to those with a negative RF (12/12 active versus 21/26). In 2 patients, RF reverted from positive to negative when their disease became clinically inactive. Only 7/28 patients with a positive RF had co-morbid diseases previously associated with RF: Hepatitis B or C (3), autoimmune liver disease (1), SLE (1), SLE/MCTD (2). All patients tested for anti-CCP (including 9/12 with high positive RF and 7/16 with low titre RF) were negative.

Conclusion:

RF can be positive in morphea, and it may be used as a marker of disease activity. Anti-CCP was not positive in any of our patients with morphea. RF seropositivity is not a marker of RA in patients with morphea and likely connotes B-cell dysregulation in these patients.

To cite this abstract, please use the following information:
Kellet, Cristián Vera, Dutz, Jan P.; Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Profile in Patients with Morphea [abstract]. Arthritis Rheum 2009;60 Suppl 10 :796
DOI: 10.1002/art.25876

Abstract Supplement

Meeting Menu

2009 ACR/ARHP